Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: A quantitative 2-[14C]deoxyglucose study

Brain Research

Volumn 962, Issue 1-2, 2003, Pages 169-179

  Freedland, Cory S ^a   Whitlow, Christopher T ^a   Smith, Hilary R ^a   Porrino, Linda J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid; Deoxyglucose; SR141716A; Tolerance

Indexed keywords

CANNABINOID RECEPTOR ANTAGONIST; CARBON 14; DEOXYGLUCOSE; GLUCOSE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR TERATOLOGY; BRAIN METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEEDING BEHAVIOR; FOOD; GLUCOSE UTILIZATION; HYPOTHALAMUS; INSTRUMENTAL CONDITIONING; LIMBIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; CONDITIONING, OPERANT; DEOXYGLUCOSE; DRUG TOLERANCE; FEEDING BEHAVIOR; GLYCOLYSIS; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REWARD; TIME FACTORS;

EID: 0037423065     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03999-9     Document Type: Article

References (50)

1. Aceto M.D., Scates S.M., Lowe J.A., Martin B.R. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur. J. Pharmacol. 282:1995;R1-2.
2. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berlin). 132:1997;104-106.
3. Beardsley P.M., Balster R.L., Harris L.S. Dependence on tetrahydrocannabinol in rhesus monkeys. J. Pharmacol. Exp. Ther. 239:1986;311-319.
4. Beardsley P.M., Martin B.R. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal. Eur. J. Pharmacol. 387:2000;47-53.
5. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272:1997;22330-22339.
6. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., Sim-Selley L.J. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem. 73:1999;2447-2459.
7. Brodkin J., Moerschbaecher J.M. SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J. Pharmacol. Exp. Ther. 282:1997;1526-1532.
8. Carroll M.E., Carmona G. Effects of food FR and food deprivation on disruptions in food-maintained performance of monkeys during phencyclidine withdrawal. Psychopharmacology (Berlin). 104:1991;143-149.
9. Carroll M.E., Lac S.T., Asencio M., Keenan R.M. Nicotine dependence in rats. Life Sci. 45:1989;1381-1388.
10. Collins D.R., Pertwee R.G., Davies S.N. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115:1995;869-870.
11. Colombo G., Agabio R., Fa M., Guano L., Lobina C., Loche A., Reali R., Gessa G.L. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol. 33:1998;126-130.
12. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
13. 14C]deoxyglucose method for use in freely moving rats. Brain Res. 499:1989;87-92.
14. Deroche V., Le Moal M., Piazza P.V., Soubrie P. SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacology (Berlin). 157:2001;254-259.
15. Di Marzo V., Berrendero F., Bisogno T., Gonzalez S., Cavaliere P., Romero J., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J. Neurochem. 74:2000;1627-1635.
16. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
17. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410:2001;822-825.
18. C. Freedland, C. Whitlow, M. Miller, L. Porrino, Dose-dependent effects of delta-9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat, Synapse (2002) in press.
19. Freedland C.S., Poston J.S., Porrino L.J. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol. Biochem. Behav. 67:2000;265-270.
20. Freedland C.S., Sharpe A.L., Samson H.H., Porrino L.J. Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin. Exp. Res. 25:2001;277-282.
21. Freedland C.S., Whitlow C.T., Miller M.D., Porrino L.J. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse. 45:2002;134-142.
22. Gonzalez-Lima F., Helmstetter F.J., Agudo J. Functional mapping of the rat brain during drinking behavior: a fluorodeoxyglucose study. Physiol. Behav. 54:1993;605-612.
23. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
24. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., Frank R.A. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry. 58:2001;322-328.
25. Jarbe T.U., Lamb R.J., Lin S., Makriyannis A. (R)-Methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berlin). 156:2001;369-380.
26. Mansbach R.S., Rovetti C.C., Winston E.N., Lowe J.A. 3rd. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berlin). 124:1996;315-322.
27. McAllister S.D., Griffin G., Satin L.S., Abood M.E. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J. Pharmacol. Exp. Ther. 291:1999;618-626.
28. Mogenson G., Yang C. The contribution of basal forebrain to limbic-motor integration and the mediation of motivation to action. Adv. Exp. Med. Biol. 295:1991;267-290.
29. Navarro M., Hernandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., Rodriguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 8:1997;491-496.
30. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
31. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego, CA.
32. Richardson J.D., Aanonsen L., Hargreaves K.M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-4.
33. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Breliere J.C., Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
34. Robbins T., Everitt B. Neurobehavioural mechanisms of reward and motivation. Curr. Opin. Neurobiol. 6:1996;228-236.
35. Rodriguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
36. Romero J., Garcia-Palomero E., Castro J.G., Garcia-Gil L., Ramos J.A., Fernandez-Ruiz J.J. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res. Mol. Brain Res. 46:1997;100-108.
37. Salamone J., Cousins M., Snyder B. Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci. Biobehav. Rev. 21:1997;341-359.
38. Sanudo-Pena M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. Eur. J. Pharmacol. 391:2000;269-274.
39. Schulteis G., Markou A., Gold L.H., Stinus L., Koob G.F. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J. Pharmacol. Exp. Ther. 271:1994;1391-1398.
40. Serra S., Carai M.A., Brunetti G., Gomez R., Melis S., Vacca G., Colombo G., Gessa G.L. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur. J. Pharmacol. 430:2001;369-371.
41. Sim L.J., Hampson R.E., Deadwyler S.A., Childers S.R. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J. Neurosci. 16:1996;8057-8066.
42. Simiand J., Keane M., Keane P.E., Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. 9:1998;179-181.
43. Sim-Selley L.J., Brunk L.K., Selley D.E. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414:2001;135-143.
44. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28:1977;897-916.
45. Tsou K., Patrick S.L., Walker J.M. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280:1995;R13-15.
46. Vivian J.A., Kishioka S., Butelman E.R., Broadbear J., Lee K.O., Woods J.H. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J. Pharmacol. Exp. Ther. 286:1998;697-703.
47. Whitlow C.T., Freedland C.S., Porrino L.J. Metabolic mapping of the time-dependent effects of Delta(9)-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berlin). 161:2002;129-136.
48. Wiley J.L., Barrett R.L., Lowe J., Balster R.L., Martin B.R. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995;669-676.
49. Wiley J.L., Lowe J.A., Balster R.L., Martin B.R. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;1-6.
50. Woolverton W.L., Kleven M.S. Evidence for cocaine dependence in monkeys following a prolonged period of exposure. Psychopharmacology (Berlin). 94:1988;288-291.